# A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

> **NCT01298141** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 171 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** agalsidase alfa

## Key facts

- **NCT ID:** NCT01298141
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-10
- **Primary completion:** 2017-09-25
- **Final completion:** 2017-09-25
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01298141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01298141, "A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01298141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*